




EMLc
ATC codes: J02AA01

| | |
|--------------------------|---|
| Indication | Coccidioidomycosis ICD11 code: 1F25.Z |
| INN | Amphotericin B |
| Medicine type | Chemical agent |
| List type | Core (EML) (EMLc) |
| Formulations | Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex) ; 50 mg in vial powder for injection (as sodium deoxycholate) |
| EML status history | <ul style="list-style-type: none"> First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 1984 (TRS 722) Changed in 2003 (TRS 920) Changed in 2007 (TRS 950) Changed in 2009 (TRS 958) Changed in 2013 (TRS 985) Changed in 2023 (TRS 1049) |
| Sex | All |
| Age | Also recommended for children |
| Therapeutic alternatives | The recommendation is for this specific medicine |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  |
| Wikipedia | Amphotericin B  |
| DrugBank | Amphotericin b  |

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for amphotericin B on the EML and EMLc be amended to list the liposomal and deoxycholate formulations separately, and the inclusion of a note to indicate that liposomal amphotericin B is the preferred formulation because of its better safety profile.

